Estrogen receptor mutations found in breast cancer metastases integrated with the molecular pharmacology of selective ER modulators.
|
| Abstract |
The consistent reports of mutations at Asp538 and Tyr537 in helix 12 of the ligand-binding domain (LBD) of estrogen receptors (ERs) from antihormone-resistant breast cancer metastases constitute an important advance. The mutant amino acids interact with an anchor amino acid, Asp351, to close the LBD, thereby creating a ligand-free constitutively activated ER. Amino acids Asp 538, Tyr 537, and Asp 351 are known to play a role in either the turnover of ER, the antiestrogenic activity of the ER complex, or the estrogen-like actions of selective ER modulators. A unifying mechanism of action for these amino acids to enhance ER gene activation and growth response is presented. There is a range of mutations described in metastases vs low to zero in primary disease, so the new knowledge is of clinical relevance, thereby confirming an additional mechanism of acquired resistance to antihormone therapy through cell population selection pressure and enrichment during treatment. Circulating tumor cells containing ER mutations can be cultured ex vivo, and tumor tissues can be grown as patient-derived xenografts to add a new dimension for testing drug susceptibility for future drug discovery.
|
|---|---|
| Authors | V Craig Jordan, Ramona Curpan, Philipp Y Maximov |
| Journal | Journal of the National Cancer Institute (J Natl Cancer Inst) Vol. 107 Issue 6 Pg. djv075 (Jun 2015) ISSN: 1460-2105 [Electronic] United States |
| PMID | 25838462 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.) |
| Copyright | © The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: [email protected]. |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!